Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy

Brain, Behavior, and Immunity

Volumn 18, Issue 3, 2004, Pages 205-213

  Capuron, Lucile ^a   Ravaud, Alain ^b   Miller, Andrew H ^a   Dantzer, Robert ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUT BERGONIÉ   (France)

^c INSTITUT FRANÇOIS MAGENDIE   (France)

Author keywords

Cancer; Cytokine treatment; Depressive symptoms; Interferon alpha; Interleukin 2; Vulnerability

Indexed keywords

ALPHA INTERFERON; CYTOKINE; INTERLEUKIN 2;

ADULT; ANOREXIA; ARTICLE; AUTONOMIC NEUROPATHY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COPING BEHAVIOR; DEMOGRAPHY; DEPRESSION; DISEASE SEVERITY; EMOTION; EMOTIONAL DISORDER; FEMALE; HUMAN; KIDNEY CARCINOMA; LASSITUDE; MALE; MELANOMA; MOOD; PATIENT ATTITUDE; PREDICTION; PRIORITY JOURNAL; PSYCHOSOMATIC DISORDER; RATING SCALE; SLEEP; SLEEP DISORDER; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; SUICIDAL BEHAVIOR; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADAPTATION, PSYCHOLOGICAL; AFFECT; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DEPRESSION; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; SOCIAL SUPPORT;

EID: 1842526608     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2003.11.004     Document Type: Article

References (29)

1. Breslau N., Roth T., Rosenthal L., Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adult. Biol. Psychiatry. 39:1996;411-418.
2. Bruchon-Schweitzer M., Cousson F., Quintard B., Nuissier J., Rascle N. French adaptation of the Ways of Coping Checklist. Percept. Mot. Skills. 83:1996;104-106.
3. Buter J., de Vries E.G., Sleijfer D.T., Willemse P.H., Mulder N.H. Neuropsychiatric symptoms during treatment with interleukin-2. Lancet. 341:1993;628.
4. Capuron L., Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N. Engl. J. Med. 340:1999;1370.
5. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., Miller A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 26:2002;643-652.
6. Capuron L., Raison C.L., Musselman D.L., Lawson D.H., Nemeroff C.B., Miller A.H. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am. J. Psychiatry. 160:2003;1342-1345.
7. Denicoff K.D., Rubinow D.R., Papa M.Z., Simpson C., Seipp C.A., Lotze M.T., Chang A.E., Rosenstein D., Rosenberg S.A. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 107:1987;293-300.
8. Exton M.S., Baase J., Pithan V., Goebel M.U., Limmroth V., Schedlowski M. Neuropsychological performance and mood states following acute interferon-beta-1b administration in healthy males. Neuropsychobiology. 45:2002;199-204.
9. Ford D.E., Kamerow D.B. Epidemiologic study of sleep disturbances and psychiatric disorder: an opportunity for prevention. JAMA. 262:1989;1479-1484.
10. Ford D.E., Cooper-Patrick L. Sleep disturbances and mood disorders: an epidemiologic perspective. Depress Anxiety. 14:2001;3-6.
11. Gumnick J.F., Nemeroff C.B. Problems with currently available antidepressants. J. Clin. Psychiatry. 61(Suppl 10):2000;5-15.
12. Hauser P., Khosla J., Aurora H., Laurin J., Kling M.A., Hill J., Gulati M., Thornton A.J., Schultz R.L., Valentine A.D., Meyers C.A., Howell C.D. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol. Psychiatry. 7:2002;942-947.
13. Kammula U.S., White D.E., Rosenberg S.A. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 83:1998;797-805.
14. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H. Interferon-alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14:1996;7-17.
15. Michalak E.E., Wilkinson C., Hood K., Srinivasan J., Dowrick C., Dunn G. Prevalence and risk factors for depression in a rural setting. Results from the North Wales arm of the ODIN project. Soc. Psychiatry Psychiatr. Epidemiol. 37:2002;567-571.
16. Miyaoka H., Otsubo T., Kamijima K., Ishii M., Onuki M., Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am. J. Psychiatry. 156:1999;1120.
17. Monk T.H., Folkard S., Leng V.C., Weitzman E.D. Circadian rhythms in subjective alertness and core body temperature. Chronobiologia. 10:1983;49-55.
18. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 134:1979;382-389.
19. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., Greiner K., Nemeroff C.B., Miller A.H. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 344:2001;961-966.
20. Négrier S., Ravaud A., Delva R., Chevreau C., Douillard J.Y., Fargeot P., Devron M., Gomez F. Combination of cytokines in metastatic renal cell carcinoma; is the subcutaneous route less active than the intravenous route. Proc. Am. Soc. Clin. Oncol. 18:1999;331a. (abstract).
21. Otsubo T., Miyaoka H., Kamijima K., Onuki M., Ishii M., Mitamura K. Depression during interferon therapy in chronic hepatitis C patients - a prospective study. Seishin Shinkeigaku Zasshi (Jpn.). 99:1997;101-127.
22. Pennebaker J.W. The Psychology of Physical Symptoms. 1982;Springer, New York.
23. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry. 58:2001;445-452.
24. Sarason I.G., Levine H.M., Basham R.B., Sarason B.R. Assessing social support: the social support questionnaire. J. Pers. Soc. Psychol. 44:1983;127-139.
25. Schroevers M.J., Ranchor A.V., Sanderman R. The role of social support and self-esteem in the presence and course of depressive symptoms: a comparison of cancer patients and individuals from the general population. Soc. Sci. Med. 57:2003;375-385.
26. Sleijfer D.T., Janssen R.A., Buter J., de Vries E.G., Willemse P.H., Mulder N.H. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J. Clin. Oncol. 10:1992;1119-1123.
27. Snaith R.P., Harrop F.M., Newby D.A., Teale C. Grade scores of the Montgomery-Asberg depression and the clinical anxiety scales. Br. J. Psychiatry. 148:1986;599-601.
28. Vitaliano P.P., Russo J., Carr J.E., Maiuro R.D., Becker J. The ways of coping checklist: revision and psychometric properties. Multivariate Behav. Res. 20:1985;3-26.
29. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67:1983;361-370.